Neumora Therapeutics Inc. Common Stock (NMRA)
Stock · NASDAQ · Health Care
$0.4839as of 10/16/2026
Price chart
Active signals
NMRA Signal Track Record
How signals performed across all stocks →What NMRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 18 | -11.4% | 39% | September 28, 2026 |
| Bollinger Band Breakdown | 15 | -5.6% | 40% | September 11, 2026 |
| Bollinger Band Breakout | 12 | -4.2% | 42% | April 30, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -8.2% | 25% | April 9, 2026 |
| Any 20-session window (baseline) | -6.9% | 41% |
Computed by MarketWall from daily closing prices since July 1, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develop…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 63
- Website
- neumoratx.com/
Fundamentals
- 1-day range
- $0.3602$0.4595
- Market cap
- $303.87M
- P/E (trailing)
- —
- P/E (forward)
- -0.64
- EPS (trailing)
- $-1.23
- Dividend yield
- —
- Beta
- 3.12
- Avg. volume
- 1.33M
Forecasts
7 analyst ratings
Neumora Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
- IKTInhibikase Therapeutics Inc. Common Stock$1.65▼ 9.84%Market cap $318.20MP/E —$1.33$2.61
- EDITEditas Medicine Inc. Common Stock$2.35▼ 3.69%Market cap $283.93MP/E —$1.66$4.33
- LCTXLineage Cell Therapeutics Inc. Common Stock$0.98▼ 1.01%Market cap $281.71MP/E —$0.8823$2.09
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
| IKT Inhibikase Therapeutics Inc. Common Stock | $318.20M | — | $1.65 | ▼ 9.84% | $1.33$2.61 |
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $2.35 | ▼ 3.69% | $1.66$4.33 |
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $0.98 | ▼ 1.01% | $0.8823$2.09 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Biotech Options Buzz: UTHR, NMRA, EWTXYahoo · 9/18/2026
Insider Activity
Insider Actions →- Daljit Singh Aurora · August 21, 2026 · Option Exercise21.1K @ $0.72
- Daljit Singh Aurora · August 21, 2026 · Option Exercise20.6K @ $0.72
- Daljit Singh Aurora · August 21, 2026 · Sale21.1K @ $1.6
- Daljit Singh Aurora · August 21, 2026 · Sale20.6K @ $1.59
- Michael Lee Milligan · August 20, 2026 · Grant175.0K
- Joshua Pinto · August 20, 2026 · Grant500.0K
- Daljit Singh Aurora · August 20, 2026 · Grant200.0K
- Daljit Singh Aurora · August 20, 2026 · Option Exercise21.7K @ $0.72
- Daljit Singh Aurora · August 20, 2026 · Option Exercise45.0K @ $0.72
- Daljit Singh Aurora · August 20, 2026 · Option Exercise67.7K @ $0.72
- Daljit Singh Aurora · August 20, 2026 · Sale66.7K @ $1.51
- Daljit Singh Aurora · August 20, 2026 · Sale67.7K @ $1.51
- Duncan Jason · August 20, 2026 · Grant375.0K
- Paul L. Berns · August 20, 2026 · Grant500.0K
- Daljit Singh Aurora · August 19, 2026 · Option Exercise30.9K @ $0.72
Institutional Ownership
March 31, 2026
- Total shares held
- 71.23M
- Total value held
- $137.26M
- Institutional holders
- 109
- Unknown8.50M
- Unknown6.09M
- Unknown5.10M
- Unknown4.46M
- Unknown3.89M
- Unknown3.50M
- Unknown3.31M
- Unknown2.75M
- Unknown2.56M
- Unknown2.12M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
NMRA noted among top stock movers today
NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.
NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.